secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2022-01-06T23:59:59+00:00
Accession:  0001493152-22-000588
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics CSO Charles H. Randall resigns effective Dec 31, 2021
-------------------------------------------------------------------------

- Charles H. Randall resigned as Chief Strategy Officer on December 31, 2021.
- Company and Mr. Randall are finalizing terms of release and severance under his employment agreement.
- No replacement or interim appointment has been announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000149315222000588/0001493152-22-000588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000149315222000588/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-000588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer